-
Posted by
Two Blokes Jun 25 -
Filed in
Stock
-
2 views
VOQUEZNA's FDA exclusivity through 2032 and superior efficacy in GERD and H. pylori create a strong competitive moat in a $3.2B+ market. Rapid commercial uptake, robust DTC marketing, and >80% insurance coverage have driven $55M+ first-year sales and 390,000+ prescriptions. Discounted cash flow analysis supports a $14/share price target (43% upside potential), with near-term catalysts in sales growth, EU partnerships, and pipeline expansion.
